© 2017 Pharmstandard Ventures
enGene
Montreal, Canada
Year of Investment: 2015
Montreal, Canada
Year of Investment: 2015
Strategic Deal with Janssen in October, 2015
Strategic Deal with Takeda in January 2016
Strategic Deal with Takeda in January 2016
enGene
Montreal, Canada
Year of Investment: 2015
Montreal, Canada
Year of Investment: 2015
Strategic Deal with Janssen in October, 2015
Strategic Deal with Takeda in January 2016
Strategic Deal with Takeda in January 2016
enGene Inc. is a biotechnology company developing a proprietary non-viral gene therapy platform for localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility including DNA and various forms of RNA with broad tissue and disease applications. In addition to developing EG-70 for BCG-unresponsive NMIBC, enGene is developing unique genetic medicines for respiratory indications and the company is evolving its technology to enable applications in multiple mucosal tissues with areas of high unmet medical need.
For more information, please visit:
www.engeneinc.com
For more information, please visit:
www.engeneinc.com
Pharmstandard Ventures is looking for innovative drug discovery/development projects targeting the unmet medical needs or providing dramatic advantages over the competition globally